Kadian

The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Kadian has widespread effects in the central nervous system and on smooth muscle. .
[PubChem].

Medicinal name:
  • Morphine Sulfate 150 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 200 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 70 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 20 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 80 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 50 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 100 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 60 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 30 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 10 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 40 MG Extended Release Oral Capsule [Kadian]
  • Morphine Sulfate 130 MG Extended Release Oral Capsule [Kadian]

Kadian - Pharmacology:

The precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.

Kadian mini report

Kadian NDA
NDA - A product marketed under an approved New Drug Application
Kadian CAPSULE, EXTENDED RELEASE
CAPSULE, EXTENDED RELEASE
Kadian HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Kadian global name
morphine sulfate
Kadian global name
MORPHINE SULFATE
Start - Stop data
START DATA:
2001-Nov-07
Start - Stop data
STOP DATA
not occurred

Kadian for patients

If clinically advisable, patients receiving ORAMORPH SR brand of morphine sulfate sustained release tablets, should be given the following instructions by the physician:

  1. Kadian may produce psychological and/or physical dependence. For this reason, the dose of the drug should not be increased without consulting a physician.
  2. Kadian may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery).
  3. Kadian should not be taken with alcohol or other CNS de-pressants (sleep aids, tranquilizers) because additive effects, including CNS depression, may occur. A physician should be consulted if other prescription and/or over-the-counter medications are currently being used or are prescribed for future use.
  4. For women of childbearing potential, who become or are planning to become pregnant, a physician should be consulted regarding analgesics and other drug use.

Storage: ORAMORPH SR Tablets should be stored in unopened containers at or below room temperature.

Caution: Federal law prohibits dispensing without prescription. Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.

Safety and Handling Instructions: ORAMORPH SR is supplied as tablets that pose little risk of direct exposure to health care personnel and should be handled and disposed of in accordance with hospital policy. Patients and their families should be instructed to dispose of ORAMORPH SR tablets, that are no longer needed, down the toilet.

Kadian Interactions

Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.

Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. In these patients, the mixed agonist/antagonist may alter the analgesic effect or may precipitate withdrawal symptoms.

Kadian Contraindications

ORAMORPH SR is contraindicated in patients with respiratory depression in the absence of resuscitative equipment, in patients with acute or severe bronchial asthma and in patients with known hypersensitivity to morphine.

ORAMORPH SR is contraindicated in any patient who has or is suspected of having a paralytic ileus.

Manufacturers name:

  • Actavis Kadian LLC
  • Actavis Pharma, Inc
  • Bryant Ranch Prepack
  • St Marys Medical Park Pharmacy
  • STAT RX USA LLC
  • Physicians Total Care, Inc
  • Lake Erie Medical DBA Quality Care Products LLC

Generic name, Overdose, Half Life Kadian, Food Interactions, Chemical, etc..

Kadian see also FDA report


Chemical structure:
H O H N O O H H H H H H H H H H H H H H H H H C17H19NO3 2D chemical structure C17H19NO3 SVG | 2D structure Morphine | Hydromorphone | chemical names, chemical properties, classification C17H19NO3